“When Offered to Participate”: A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical Trials
Open accessThe DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
Background: Patient participation in clinical trials is vital for knowledge advancement and outcomes improvement. Few adult cancer patients participate in trials. Although patient decision-making about trial participation has been frequently examined, the participation rate for patients actually offered a trial is unknown. Methods: A systematic review and meta-analysis using 3 major search engines was undertaken. We identified studies from January 1, 2000, to January 1, 2020, that examined clinical trial participation in the United States. Studies must have specified the numbers of patients offered a trial and the number enrolled. A random effects model of proportions was used. All statistical tests were 2-sided. Results: We identified 35 studies (30 about treatment trials and 5 about cancer control trials) among which 9759 patients were offered trial participation. Overall, 55.0% (95% confidence interval [CI] = 49.4% to 60.5%) of patients agreed to enroll. Participation rates did not differ between treatment (55.0%, 95% CI = 48.9% to 60.9%) and cancer control trials (55.3%, 95% CI = 38.9% to 71.1%; P = .98). Black patients participated at similar rates (58.4%, 95% CI = 46.8% to 69.7%) compared with White patients (55.1%, 95% CI = 44.3% to 65.6%; P = .88). The main reasons for nonparticipation were treatment choice or lack of interest. Conclusions: More than half of all cancer patients offered a clinical trial do participate. These findings upend several conventional beliefs about cancer clinical trial participation, including that Black patients are less likely to agree to participate and that patient decision-making is the primary barrier to participation. Policies and interventions to improve clinical trial participation should focus more on modifiable systemic structural and clinical barriers, such as improving access to available trials and broadening eligibility criteria.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Conducting Meta-Analyses in R with the metafor Package
Viechtbauer, W. (2010) · Journal of Statistical Software · doi:10.18637/jss.v036.i03 · Cited by 20,464
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2009) · doi:10.1002/9780470743386 · Cited by 14,225
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2021) · doi:10.1002/9781119558378 · Cited by 9,799
Unequal treatment: confronting racial and ethnic disparities in health care
(2003) · Choice Reviews Online · doi:10.5860/choice.40-5843 · Cited by 7,043
A basic introduction to fixed-effect and random-effects models for meta-analysis
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2010) · Research Synthesis Methods · doi:10.1002/jrsm.12 · Cited by 6,793 · cited 2×
“statistic greater than 50% suggests that a random effects approach, which accounts for both within- and between-study variation, is preferable (17,18,21,22).”
BackgroundThe combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380
Capps, L. (2003) · JAMA · doi:10.1001/jama.290.18.2487-b · Cited by 4,526
Meta-analysis in clinical trials revisited
DerSimonian, R., & Laird, N. (2015) · Contemporary Clinical Trials · doi:10.1016/j.cct.2015.09.002 · Cited by 2,677
Barendregt, J. J., Doi, S. A., Lee, Y. Y., Norman, R. E., & Vos, T. (2013) · Journal of Epidemiology and Community Health · doi:10.1136/jech-2013-203104 · Cited by 2,169
Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities
Murthy, V. H., Krumholz, H. M., & Gross, C. P. (2004) · JAMA · doi:10.1001/jama.291.22.2720 · Cited by 2,078
Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects Model
Viechtbauer, W. (2005) · Journal of Educational and Behavioral Statistics · doi:10.3102/10769986030003261 · Cited by 1,699 · cited 1×
“A restricted maximumlikelihood estimator of the between-study variance was used (23,24).”
MethodBarriers to recruiting underrepresented populations to cancer clinical trials: a systematic review
Ford, J. G., Howerton, M. W., Lai, G. Y., Gary, T. L., Bolen, S., Gibbons, M. C., Tilburt, J., Baffi, C., Tanpitukpongse, T. P., Wilson, R. F., et al. (2008) · Cancer · doi:10.1002/cncr.23157 · Cited by 1,083
A comparison of heterogeneity variance estimators in simulated random‐effects meta‐analyses
Langan, D., Higgins, J. P. T., Jackson, D., Bowden, J., Veroniki, A. A., Kontopantelis, E., Viechtbauer, W., & Simmonds, M. (2019) · Research Synthesis Methods · doi:10.1002/jrsm.1316 · Cited by 1,074 · cited 1×
“A restricted maximumlikelihood estimator of the between-study variance was used (23,24).”
MethodRacial and Ethnic Disparities in the Receipt of Cancer Treatment
Shavers, V. L. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.5.334 · Cited by 950
Are Racial and Ethnic Minorities Less Willing to Participate in Health Research?
Wendler, D., Kington, R., Madans, J., Wye, G. V., Christ-Schmidt, H., Pratt, L. A., Brawley, O. W., Gross, C. P., & Emanuel, E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0030019 · Cited by 854
Lara, P. N., Higdon, R., Lim, N., Kwan, K., Tanaka, M., Lau, D. H. M., Wun, T., Welborn, J., Meyers, F. J., Christensen, S., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1728 · Cited by 588
A comparison of statistical methods for meta‐analysis
Brockwell, S. E., & Gordon, I. R. (2001) · Statistics in Medicine · doi:10.1002/sim.650 · Cited by 573 · cited 2×
“statistic greater than 50% suggests that a random effects approach, which accounts for both within- and between-study variation, is preferable (17,18,21,22).”
BackgroundLoree, J. M., Anand, S., Dasari, A., Unger, J. M., Gothwal, A., Ellis, L. M., Varadhachary, G., Kopetz, S., Overman, M. J., & Raghav, K. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1870 · Cited by 570 · cited 1×
“This observation seems surprising given the repeated observations that minority patients are underrepresented in clinical cancer research (2,12).”
BackgroundSelf-citationUnger, J. M., Vaidya, R., Hershman, D. L., Minasian, L. M., & Fleury, M. E. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy221 · Cited by 570
Self-citationSateren, W. B., Trimble, E. L., Abrams, J., Brawley, O., Breen, N., Ford, L., McCabe, M., Kaplan, R., Smith, M., Ungerleider, R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.056 · Cited by 535
Evaluating patient and stakeholder engagement in research: moving from theory to practice
Esmail, L., Moore, E., & Rein, A. (2015) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.14.79 · Cited by 502 · cited 1×
“More broadly, external advisory groups, especially that include patient advocates, could help researchers design trials that more readily incorporate elements to make trial participation more attractive to patients (73,74).”
BackgroundKim, E. S., Bruinooge, S. S., Roberts, S., Ison, G., Lin, N. U., Gore, L., Uldrick, T. S., Lichtman, S. M., Roach, N., Beaver, J. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7916 · Cited by 485
Barriers to Clinical Trial Participation by Older Women With Breast Cancer
Kemeny, M. M., Peterson, B. L., Kornblith, A. B., Muss, H. B., Wheeler, J., Levine, E., Bartlett, N., Fleming, G., & Cohen, H. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.124 · Cited by 465
Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients with Cancer
Hamel, L. M., Penner, L. A., Albrecht, T. L., Heath, E., Gwede, C. K., & Eggly, S. (2016) · Cancer Control · doi:10.1177/107327481602300404 · Cited by 463
Henley, S. J., Anderson, R. N., Thomas, C. C., Massetti, G. M., Peaker, B., & Richardson, L. C. (2017) · MMWR. Surveillance Summaries · doi:10.15585/mmwr.ss6614a1 · Cited by 419
Patient Income Level and Cancer Clinical Trial Participation
Unger, J. M., Hershman, D. L., Albain, K. S., Moinpour, C. M., Petersen, J. A., Burg, K., & Crowley, J. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.4553 · Cited by 290
Self-citationTejeda, H. A., Green, S. B., Trimble, E. L., Ford, L., High, J. L., Ungerleider, R. S., Friedman, M. A., & Brawley, O. W. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.12.812 · Cited by 269
Oncology Practice During the COVID-19 Pandemic
Schrag, D., Hershman, D. L., & Basch, E. (2020) · JAMA · doi:10.1001/jama.2020.6236 · Cited by 252
Self-citationInfluence of Clinical Communication on Patients' Decision Making on Participation in Clinical Trials
Albrecht, T. L., Eggly, S. S., Gleason, M. E. J., Harper, F. W. K., Foster, T. S., Peterson, A. M., Orom, H., Penner, L. A., & Ruckdeschel, J. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8114 · Cited by 248
Unger, J. M., Moseley, A., Symington, B., Chavez-MacGregor, M., Ramsey, S. D., & Hershman, D. L. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.1235 · Cited by 217
Self-citationEnrollment of African Americans Onto Clinical Treatment Trials: Study Design Barriers
Adams-Campbell, L. L., Ahaghotu, C., Gaskins, M., Dawkins, F. W., Smoot, D., Polk, O. D., Gooding, R., & DeWitty, R. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.160 · Cited by 199
Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation
Unger, J. M., Hershman, D. L., Fleury, M. E., & Vaidya, R. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5953 · Cited by 181
Self-citationGross, C. P., Filardo, G., Mayne, S. T., & Krumholz, H. M. (2005) · Cancer · doi:10.1002/cncr.20792 · Cited by 172
Participation in Cancer Clinical Trials: Why Are Patients Not Participating?
Byrne, M. M., Tannenbaum, S. L., Glück, S., Hurley, J., & Antoni, M. (2014) · Medical Decision Making · doi:10.1177/0272989x13497264 · Cited by 169
Simon, M. S., Du, W., Flaherty, L., Philip, P. A., Lorusso, P., Miree, C., Smith, D., & Brown, D. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.005 · Cited by 163
Accrual to cancer clinical trials: Directions from the research literature
Gotay, C. C. (1991) · Social Science & Medicine · doi:10.1016/0277-9536(91)90214-w · Cited by 162
Siminoff, L. A., Zhang, A., Colabianchi, N., Sturm, C. M. S., & Shen, Q. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.6.1203 · Cited by 149
Pfister, D. G., Rubin, D. M., Elkin, E. B., Neill, U. S., Duck, E., Radzyner, M. H., & Bach, P. B. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.3151 · Cited by 148
Borno, H. T., Zhang, L., Siegel, A. P., Chang, E. G., & Ryan, C. J. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0628 · Cited by 136
Langford, A. T., Resnicow, K., Dimond, E. P., Denicoff, A. M., Germain, D. S., McCaskill‐Stevens, W., Enos, R. A., Carrigan, A., Wilkinson, K., & Go, R. S. (2014) · Cancer · doi:10.1002/cncr.28483 · Cited by 131
Go, R. S., Frisby, K. A., Lee, J., Mathiason, M. A., Meyer, C. M., Ostern, J. L., Walther, S. M., Schroeder, J. E., Meyer, L. A., & Umberger, K. E. (2005) · Cancer · doi:10.1002/cncr.21597 · Cited by 120
Unger, J. M., Hershman, D. L., Osarogiagbon, R. U., Gothwal, A., Anand, S., Dasari, A. N., Overman, M. J., Loree, J. M., & Raghav, K. P. S. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa034 · Cited by 120
Self-citationJavid, S. H., Unger, J. M., Gralow, J. R., Moinpour, C. M., Wozniak, A. J., Goodwin, J. W., Lara, P. N., Williams, P. A., Hutchins, L. F., Gotay, C. C., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0384 · Cited by 107
Self-citationSears, S. R., Stanton, A. L., Kwan, L. C., KRUPNICK, J. L., Rowland, J. H., Meyerowitz, B. E., & Ganz, P. A. (2003) · PubMed · Cited by 66
Penberthy, L. T., Brown, R., Wilson-Genderson, M., Dahman, B. A., Ginder, G. D., & Siminoff, L. A. (2012) · Clinical Trials · doi:10.1177/1740774512458992 · Cited by 64
Patients' Perceptions of Physicians Communication and Outcomes of the Accrual to Trial Process
Grant, C. H., Cissna, K. N., & Rosenfeld, L. B. (2000) · Health Communication · doi:10.1207/s15327027hc1201_02 · Cited by 62
Germain, D. S., Denicoff, A. M., Dimond, E. P., Carrigan, A. C., Enos, R. A., González, M. M., Wilkinson, K. A., Mathiason, M. A., Duggan, B., Einolf, S., et al. (2014) · Journal of Oncology Practice · doi:10.1200/jop.2013.001194 · Cited by 61
Aycinena, A. C., Valdovinos, C., Crew, K. D., Tsai, W. Y., Mata, J. M., Sandoval, R., Hershman, D. L., & Greenlee, H. (2016) · Journal of Immigrant and Minority Health · doi:10.1007/s10903-015-0310-1 · Cited by 57
Self-citationCopur, M. S., Ramaekers, R. C., Gönen, M., Gulzow, M., Hadenfeldt, R., Fuller, C., Scott, J., Einspahr, S., Benzel, H., Mickey, M., et al. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2015.005736 · Cited by 49
Harvey, R. D., Bruinooge, S. S., Chen, L., Garrett-Mayer, E. S., Rhodes, W., Stepanski, E. J., Uldrick, T. S., Ison, G., Khozin, S., Rubinstein, W. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3857 · Cited by 47
Systematic review of cancer treatment programmes in remote and rural areas
Campbell, N. C., Ritchie, L. D., Cassidy, J., & Little, J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690498 · Cited by 46
A Community Cancer Center Program: Getting to the Next Level
Petrelli, N. J. (2010) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2009.11.015 · Cited by 40
Geographic Proximity and Racial Disparities in Cancer Clinical Trial Participation
Kanarek, N., Tsai, H.-L., Metzger-Gaud, S., Damron, D. J., Guseynova, A., Klamerus, J. F. A., & Rudin, C. M. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0102 · Cited by 37
Identifying Barriers Associated With Enrollment of Patients With Lung Cancer into Clinical Trials
Horn, L., Keedy, V. L., Campbell, N., y García, G. G., Hayes, A., Spencer, B., Carbone, D. P., Sandler, A. B., & Johnson, D. H. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.03.008 · Cited by 37
Krieger, J. L. R., Palmer-Wackerly, A. L., Dailey, P. M., Krok‐Schoen, J. L., Schoenberg, N. E., & Paskett, E. D. (2015) · Journal of Cancer Education · doi:10.1007/s13187-015-0789-0 · Cited by 34
Kanarek, N., Kanarek, M. S., Olatoye, D., & Carducci, M. A. (2012) · Trials · doi:10.1186/1745-6215-13-237 · Cited by 33
Mattel, C. L., Li, Y., Beckett, L. A., Chew, H. K., Christensen, S., Davies, A. M., Lam, K. S., Lau, D. H., Meyers, F. J., OʼDonnell, R. T., et al. (2004) · The Cancer Journal · doi:10.1097/00130404-200409000-00006 · Cited by 29
Sears, S. R., Stanton, A. L., Kwan, L. C., & Bevers, T. B. (2004) · Cited by 29
Factors and Outcomes of Decision Making for Cancer Clinical Trial Participation
Biedrzycki, B. A. (2011) · Oncology nursing forum · doi:10.1188/11.onf.542-552 · Cited by 27
Zafar, S. F., Heilbrun, L. K., Vishnu, P., Jasti, P., Venkatramanamoorthy, R., Ding, L., LoRusso, P. M., & Heath, E. I. (2010) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2010.09.004 · Cited by 24
Brooks, S. E., Carter, R. L., Plaxe, S. C., Basen‐Engquist, K., Rodriguez, M. J., Kauderer, J. T., Walker, J. L., Myers, T. K. N., Drake, J., Havrilesky, L. J., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.04.033 · Cited by 23
Bernard‐Davila, B., Aycinena, A. C., Richardson, J., Gaffney, A. O., Koch, P., Contento, I. R., Molmenti, C. S., Alvarez, M. C., Hershman, D. L., & Greenlee, H. (2014) · Journal of Racial and Ethnic Health Disparities · doi:10.1007/s40615-014-0076-5 · Cited by 22
Self-citationDignan, M., Evans, M. B., Kratt, P. P., Pollack, L. A., Pisu, M., Smith, J. L., Prayor-Patterson, H., Houston, P. M., Watson, C., Hullett, S., et al. (2011) · Journal of Health Care for the Poor and Underserved · doi:10.1353/hpu.2011.0069 · Cited by 16
Factors influencing clinical trial enrollment among ovarian cancer patients
Greenwade, M. M., Moore, K. N., Gillen, J. M., Ding, K., Rowland, M. R., Crim, A. K., Kleis, B., & Gunderson, C. C. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.06.035 · Cited by 12
Jirka, G. W., Bisselou, K. S., Smith, L. M., & Shonka, N. (2019) · Medical Oncology · doi:10.1007/s12032-019-1259-z · Cited by 11
Tracking clinical trial accrual strategies and barriers via a Web-based screening tool
Grubbs, S. S., Gonzalez, M., Krasna, M. J., Siegel, R. D., Bryant, D., Tschetter, L. K., Hayenga, L., Duggan, B., Germaine, D., & Denicoff, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.6586 · Cited by 2
Cited by
Chen, D. W., Lang, B. H. H., McLeod, D. S. A., Newbold, K., & Haymart, M. R. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00020-x · Cited by 590
Inclusion and diversity in clinical trials: Actionable steps to drive lasting change
Kelsey, M. D., Patrick-Lake, B., Abdulai, R., Broedl, U. C., Brown, A., Cohn, E., Curtis, L. H., Komelasky, C., Mbagwu, M., Mensah, G. A., et al. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2022.106740 · Cited by 197
Nouvini, R., Parker, P. A., Malling, C. D., Godwin, K., & Costas‐Muñiz, R. (2022) · Cancer · doi:10.1002/cncr.34454 · Cited by 56
Hagen, S., Kearney, R., Goodman, K., Best, C., Elders, A., Melone, L., Dwyer, L., Dembinsky, M., Graham, M., Agur, W., et al. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.102326 · Cited by 29
Hawke, L. J., Nelson, E., O'Brien, P., Crossley, K. M., Choong, P. F., Bunzli, S., & Dowsey, M. M. (2024) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2024.101283 · Cited by 22
Metadata
- Authors
- Unger, J. M., Hershman, D. L., Till, C., Minasian, L. M., Osarogiagbon, R. U., Fleury, M. E., & Vaidya, R.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-10-06
- Volume
- 113
- Issue
- 3
- Pages
- 244-257
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W3091769743
- Cited by
- 262
- References
- 72
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.